IMGN实时信号 | 通过Getagraph.com最大化利润

出售 116259 min ago

@ $31.23

发出时间: 8 Feb 2024 @ 22:30

回报率: 0.02%

上一信号: Feb 8 - 04:55

上一信号: 购买

回报率: 5.67 %

Live Chart Being Loaded With Signals

Commentary (10 Feb 2024 @ 04:58):

Stats
今日成交量	19.31M
平均成交量	8.29M
市值	8.73B
EPS	$0 ( 2024-04-26 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-111.55
ATR14	$0.306 (0.98%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-12	Mitchell Dean J	Sell	103 000	Common Stock
2024-02-12	Mitchell Dean J	Sell	13 090	Restricted Stock Unit
2024-02-12	Mitchell Dean J	Sell	142 667	Deferred Share Unit
2024-02-12	Mitchell Dean J	Sell	10 000	Stock Option (Right to Buy)
2024-02-12	Mitchell Dean J	Sell	10 000	Stock Option (Right to Buy)

INSIDER POWER
-100.00
Last 100 transactions
Buy: 0 \| Sell: 8 781 240

音量相关性

長: 0.24 (neutral)

短: 0.25 (neutral)

Signal:(82.516) Neutral

ImmunoGen Inc 相关性

10 最正相关
HOL	0.945
IRBT	0.93
SLNG	0.929
RTPY	0.927
KBSF	0.926
LGMK	0.92
RPID	0.919
FIBK	0.917
GBCI	0.917
LYEL	0.917

10 最负相关
AEAE	-0.941
ENTF	-0.941
CCTS	-0.941
HORI	-0.939
GHIX	-0.938
FIAC	-0.938
XPAX	-0.938
NECB	-0.936
ADAL	-0.935
ACAB	-0.935

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

ImmunoGen Inc 相关性 - 货币/商品

-0.22
( neutral )

0.48
( neutral )

0.55
( weak )

-0.04
( neutral )

-0.01
( neutral )

0.26
( neutral )

ImmunoGen Inc 财务报表

Annual	2022
营收:	$108.78M
毛利润:	$108.61M (99.84 %)
EPS:	$-0.880

FY	2022
营收:	$108.78M
毛利润:	$108.61M (99.84 %)
EPS:	$-0.880

FY	2022
营收:	$108.78M
毛利润:	$108.61M (99.84 %)
EPS:	$-0.880

FY	2020
营收:	$132.30M
毛利润:	$17.71M (13.38 %)
EPS:	$-0.250

Financial Reports:

No articles found.

ImmunoGen Inc

ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.